WEST PHARMACEUTICAL SERVICES INC 8-K

What Happened

• West Pharmaceutical Services, Inc. filed an 8-K on May 5, 2026 reporting the results of its virtual 2026 Annual Meeting held May 4, 2026. As of the record date (February 27, 2026) there were 72,081,610 shares outstanding and 66,193,322 shares (91.83%) were represented at the meeting.
• All 11 director nominees were elected to serve until the 2027 Annual Meeting. The non-binding advisory "say-on-pay" vote was approved, PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2026, and a shareholder proposal to require an independent board chair was not approved.

Key Details

• Shares outstanding (record date): 72,081,610; shares represented at meeting: 66,193,322 (91.83%).
• Directors elected (all 11 nominees): Mark A. Buthman; William F. Feehery; Robert F. Friel; Eric M. Green; Janet B. Haugen; Molly E. Joseph; Deborah L. V. Keller; Myla P. Lai‑Goldman; Stephen H. Lockhart; Douglas A. Michels; Paolo Pucci.
• Say-on-pay (Proposal 2): 60,107,802 For, 3,762,206 Against, 80,429 Abstain (broker non-votes: 2,242,885).
• Auditor ratification (Proposal 3): PricewaterhouseCoopers LLP ratified — 58,509,119 For, 7,556,514 Against, 127,689 Abstain.
• Independent Board Chair policy (Proposal 4): Failed — 29,592,488 For, 34,245,125 Against, 112,824 Abstain (broker non-votes: 2,242,885).
• Notable vote opposition: Director Deborah L. V. Keller received 5,599,392 votes Against; several other directors received multi‑million Against votes but were nevertheless elected.

Why It Matters

• Governance: Re-election of the full slate of directors maintains board continuity and strategy oversight. The failure of the independent-chair proposal means no mandated change to the board chair structure resulted from this vote.
• Executive pay and oversight: Approval of the advisory say-on-pay indicates a majority of voting shareholders supported the company’s executive compensation approach, which can reduce near-term pressure for compensation changes.
• Audit continuity: Ratification of PwC as auditor confirms continuity of external financial oversight for fiscal 2026.
• Investor takeaway: These results provide clarity on shareholder sentiment about governance, pay, and audit matters; investors watching governance reforms or compensation policy should note the vote counts and the level of opposition on certain directors and proposals.